Recent changes

Jump to: navigation, search

Track the most recent changes to the wiki on this page.

Recent changes options
Legend:
N
This edit created a new page (also see list of new pages)
m
This is a minor edit
b
This edit was performed by a bot
(±123)
The page size changed by this number of bytes
Show last 50 | 100 | 250 | 500 changes in last 1 | 3 | 7 | 14 | 30 days
Hide minor edits | Show bots | Hide anonymous users | Hide registered users | Hide my edits

Show new changes starting from 09:28, 26 April 2018
   

26 April 2018

 m   08:44  Non-small cell lung cancer, ROS1-positive‎‎ (2 changes | history) . . (+1,571). . [Jwarner‎ (2×)]
 m    08:44 (cur | prev) . . (+64). . Jwarner (talk | contribs) (Investigational agents)
 m    08:41 (cur | prev) . . (+1,507). . Jwarner (talk | contribs) (Crizotinib monotherapy {{#subobject:be5391|Regimen=1}})
 m   08:32  Crizotinib (Xalkori)‎ (diff | hist) . . (+15). . Jwarner (talk | contribs)
 m   08:15  Cabozantinib (Cometriq)‎ (diff | hist) . . (+29). . Jwarner (talk | contribs) (References)
 m   08:14  Ensartinib (X-396)‎ (diff | hist) . . (+726). . Jwarner (talk | contribs)
N    08:06  Entrectinib (RXDX-101)‎ (diff | hist) . . (+2,406). . Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism, from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/entrectinib NCI Drug Dictionary]: An orally bioavailable in...")
 m   08:00  Drug index‎ (diff | hist) . . (+53). . Jwarner (talk | contribs) (E)
N    07:58  Lorlatinib (PF-06463922)‎ (diff | hist) . . (+2,285). . Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism, from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lorlatinib NCI Drug Dictionary]: An orally available, ATP-c...")

25 April 2018

 m   17:13  Acute myeloid leukemia‎ (diff | hist) . . (+29). . Jwarner (talk | contribs)
 m   15:15  Fostamatinib (Tavalisse)‎ (diff | hist) . . (+46). . Jwarner (talk | contribs)
 m   14:35  Levels of Evidence‎‎ (2 changes | history) . . (-465). . [Jwarner‎ (2×)]
 m    14:35 (cur | prev) . . (+17). . Jwarner (talk | contribs) (Non-comparative efficacy)
 m    14:32 (cur | prev) . . (-482). . Jwarner (talk | contribs) (Non-comparative efficacy)
 m   12:07  Diffuse large B-cell lymphoma‎ (diff | hist) . . (+60). . Jwarner (talk | contribs) (Lenalidomide monotherapy {{#subobject:f5ca0d|Regimen=1}})
 m   07:13  Autologous HSCT‎ (diff | hist) . . (+53). . Jwarner (talk | contribs)
 m   07:11  Hodgkin lymphoma‎ (diff | hist) . . (0). . Jwarner (talk | contribs) (References)

24 April 2018

 m   22:29  Mantle cell lymphoma‎‎ (2 changes | history) . . (+1,611). . [Jwarner‎ (2×)]
 m    22:29 (cur | prev) . . (+777). . Jwarner (talk | contribs) (Temsirolimus monotherapy {{#subobject:575bde|Regimen=1}})
 m    22:27 (cur | prev) . . (+834). . Jwarner (talk | contribs) (Ibrutinib monotherapy {{#subobject:1e0d5c|Regimen=1}})
     22:20  Diffuse large B-cell lymphoma‎‎ (5 changes | history) . . (+11,543). . [Jwarner‎ (5×)]
      22:20 (cur | prev) . . (+1,648). . Jwarner (talk | contribs) (Pixantrone monotherapy {{#subobject:bedd78|Regimen=1}})
      22:17 (cur | prev) . . (+4,109). . Jwarner (talk | contribs) (Everolimus monotherapy {{#subobject:fb3cbd|Regimen=1}})
 m    22:11 (cur | prev) . . (+2,040). . Jwarner (talk | contribs) (Gemcitabine monotherapy {{#subobject:df3421|Regimen=1}})
 m    22:05 (cur | prev) . . (+1,578). . Jwarner (talk | contribs) (Oxaliplatin monotherapy {{#subobject:308526|Regimen=1}})
 m    21:56 (cur | prev) . . (+2,168). . Jwarner (talk | contribs) (Lenalidomide monotherapy {{#subobject:f5ca0d|Regimen=1}})
 m   18:06  Stem cell mobilization‎ (diff | hist) . . (+22). . Jwarner (talk | contribs) (Stem cell mobilization)
 m   18:01  Allogeneic HSCT‎ (diff | hist) . . (+49). . Jwarner (talk | contribs)
 m   17:59  Venous thromboembolism (VTE)‎ (diff | hist) . . (+22). . Jwarner (talk | contribs) (VTE treatment)
 m   17:58  Inherited coagulopathy‎ (diff | hist) . . (+22). . Jwarner (talk | contribs) (Factor VIII deficiency (Hemophilia A), with inhibitors)
 m   16:40  Esophageal cancer‎‎ (2 changes | history) . . (+42). . [Jwarner‎ (2×)]
 m    16:40 (cur | prev) . . (+1,978). . Jwarner (talk | contribs) (Paclitaxel monotherapy {{#subobject:ed008a|Regimen=1}})
 m    16:39 (cur | prev) . . (-1,936). . Jwarner (talk | contribs) (Ramucirumab & Paclitaxel {{#subobject:fdd93f|Regimen=1}})
 m   16:38  Gastric cancer‎‎ (2 changes | history) . . (-15). . [Jwarner‎ (2×)]
 m    16:38 (cur | prev) . . (+2,016). . Jwarner (talk | contribs) (Paclitaxel monotherapy {{#subobject:2dcad9|Regimen=1}})
 m    16:37 (cur | prev) . . (-2,031). . Jwarner (talk | contribs) (Ramucirumab & Paclitaxel {{#subobject:fdd93f|Regimen=1}})
 m   16:36  Cervical cancer‎ (diff | hist) . . (-174). . Jwarner (talk | contribs)
 m   13:32  Non-small cell lung cancer‎‎ (5 changes | history) . . (+4,664). . [Jwarner‎ (5×)]
 m    13:32 (cur | prev) . . (+110). . Jwarner (talk | contribs) (Preceding treatment)
 m    13:31 (cur | prev) . . (+24). . Jwarner (talk | contribs) (Carboplatin, Pemetrexed, Bevacizumab {{#subobject:a4bca7|Regimen=1}})
 m    13:30 (cur | prev) . . (+11). . Jwarner (talk | contribs) (Cisplatin, Pemetrexed, Bevacizumab {{#subobject:836c3d|Regimen=1}})
 m    13:28 (cur | prev) . . (+722). . Jwarner (talk | contribs) (Pemetrexed & Bevacizumab {{#subobject:db5671|Regimen=1}})
 m    13:26 (cur | prev) . . (+3,797). . Jwarner (talk | contribs) (Advanced or metastatic disease, first-line, elderly or poor performance status)
 m   13:09  Talk:Non-small cell lung cancer‎ (diff | hist) . . (+512). . Jwarner (talk | contribs) (April 2018)
     09:58 (User creation log) . . User account Cdougherty (talk | contribs) was created ‎

23 April 2018

 m   16:38  Acute myeloid leukemia, IDH-mutated‎ (diff | hist) . . (+196). . Jwarner (talk | contribs) (Enasidenib monotherapy {{#subobject:226cb2|Regimen=1}})
 m   16:36  Enasidenib (Idhifa)‎‎ (2 changes | history) . . (+151). . [Jwarner‎ (2×)]
 m    16:36 (cur | prev) . . (+14). . Jwarner (talk | contribs)
 m    16:36 (cur | prev) . . (+137). . Jwarner (talk | contribs)
     12:27 (User creation log) . . User account Fvrayner (talk | contribs) was created ‎
 m   11:52  Breast cancer‎ (diff | hist) . . (+616). . Jwarner (talk | contribs) (Neoadjuvant response criteria)
 m   08:34  Non-small cell lung cancer, EGFR-mutated‎‎ (2 changes | history) . . (+258). . [Jwarner‎ (2×)]
 m    08:34 (cur | prev) . . (+128). . Jwarner (talk | contribs) (Osimertinib monotherapy {{#subobject:PYR2|Regimen=1}})
 m    08:33 (cur | prev) . . (+130). . Jwarner (talk | contribs) (Osimertinib monotherapy {{#subobject:e73636|Regimen=1}})

22 April 2018

 m   22:46  Pancreatic cancer‎‎ (2 changes | history) . . (+1,826). . [Jwarner‎ (2×)]
 m    22:46 (cur | prev) . . (+840). . Jwarner (talk | contribs) (Erlotinib & Gemcitabine {{#subobject:6d97a7|Regimen=1}})
 m    22:39 (cur | prev) . . (+986). . Jwarner (talk | contribs) (Erlotinib & Gemcitabine {{#subobject:bf797a|Regimen=1}})
 m   22:27  Non-small cell lung cancer, EGFR-mutated‎ (diff | hist) . . (-2,990). . Jwarner (talk | contribs) (Erlotinib monotherapy {{#subobject:c3c726|Regimen=1}})
 m   20:47  Editing test page‎ (diff | hist) . . (+13,239). . Jwarner (talk | contribs)
 m   20:26  Ovarian cancer‎ (diff | hist) . . (+645). . Jwarner (talk | contribs) (Placebo)